RNA-Based Gene Therapy Developed for Cystic Fibrosis
|
By LabMedica International staff writers Posted on 05 Jul 2018 |

Image: Structure of the CFTR (cystic fibrosis transmembrane conductance regulator) protein. Mutations of the CFTR gene affecting chloride ion channel function lead to dysregulation of epithelial fluid transport in the lung, pancreas, and other organs, resulting in cystic fibrosis (Photo courtesy of Wikimedia Commons).
A potential gene therapy approach for treating cystic fibrosis utilizes lipid nanoparticle-delivered chemically modified mRNA.
The promise of gene therapy for the treatment of cystic fibrosis has yet to be fully clinically realized despite years of effort toward correcting the underlying genetic defect in CFTR (cystic fibrosis transmembrane conductance regulator). Mutations in CFTR cause the disease, which is characterized by lung dehydration and mucous buildup that blocks the airway. Nanoparticle delivery of messenger RNA (mRNA) represents a powerful technology for the transfer of genetic material to cells with large, widespread populations, such as airway epithelia.
Investigators at Oregon State University (Portland, USA) and Oregon Health & Science University (Portland, USA) deployed a clinically relevant lipid-based nanoparticle (LNP) for packaging and delivery of large chemically modified CFTR mRNA (cmCFTR) to patient-derived bronchial epithelial cells.
Results published in the June 14, 2018, online edition of the journal Molecular Therapy revealed that this treatment caused in an increase in membrane-localized CFTR and rescue of its primary function as a chloride channel. Furthermore, nasal application of LNP-cmCFTR restored CFTR-mediated chloride secretion to conductive airway epithelia in CFTR knockout mice for at least 14 days. On day three post-transfection, CFTR activity peaked, recovering up to 55% of the net chloride efflux characteristic of healthy mice. This magnitude of response was superior to liposomal CFTR DNA delivery and was comparable with outcomes observed in the currently approved drug ivacaftor.
"It was a platform technology for correcting monogenic disorders and allows the same therapy to be effective for treating all cystic fibrosis patients and these systems can be repeatedly administered to a patient and the effects are reversible if someone needs to stop the therapy for any reason," said senior author Dr. Gaurav Sahay, assistant professor of pharmaceutical sciences at Oregon State University/Oregon Health & Science University.
Related Links:
Oregon State University
Oregon Health & Science University
The promise of gene therapy for the treatment of cystic fibrosis has yet to be fully clinically realized despite years of effort toward correcting the underlying genetic defect in CFTR (cystic fibrosis transmembrane conductance regulator). Mutations in CFTR cause the disease, which is characterized by lung dehydration and mucous buildup that blocks the airway. Nanoparticle delivery of messenger RNA (mRNA) represents a powerful technology for the transfer of genetic material to cells with large, widespread populations, such as airway epithelia.
Investigators at Oregon State University (Portland, USA) and Oregon Health & Science University (Portland, USA) deployed a clinically relevant lipid-based nanoparticle (LNP) for packaging and delivery of large chemically modified CFTR mRNA (cmCFTR) to patient-derived bronchial epithelial cells.
Results published in the June 14, 2018, online edition of the journal Molecular Therapy revealed that this treatment caused in an increase in membrane-localized CFTR and rescue of its primary function as a chloride channel. Furthermore, nasal application of LNP-cmCFTR restored CFTR-mediated chloride secretion to conductive airway epithelia in CFTR knockout mice for at least 14 days. On day three post-transfection, CFTR activity peaked, recovering up to 55% of the net chloride efflux characteristic of healthy mice. This magnitude of response was superior to liposomal CFTR DNA delivery and was comparable with outcomes observed in the currently approved drug ivacaftor.
"It was a platform technology for correcting monogenic disorders and allows the same therapy to be effective for treating all cystic fibrosis patients and these systems can be repeatedly administered to a patient and the effects are reversible if someone needs to stop the therapy for any reason," said senior author Dr. Gaurav Sahay, assistant professor of pharmaceutical sciences at Oregon State University/Oregon Health & Science University.
Related Links:
Oregon State University
Oregon Health & Science University
Latest BioResearch News
- New Immune Target Could Support More Precise High Blood Pressure Treatment
- Researchers Identify Shared Molecular Networks Behind Fatigue-Related Illnesses
- Blood Metabolite Signature Predicts ALS Progression and Points to Treatment Strategy
- Whole-Blood Extracellular Vesicle Analysis Captures Molecular Signals Missed by Plasma Testing
- Age-Related Genomic Differences Could Refine Treatment Decisions in Lung Cancer
- Computational Tool Identifies Central Asthma Genes for Target Discovery
- Molecular Pathway Reveals Driver of Triple-Negative Breast Cancer Spread
- D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
Channels
Clinical Chemistry
view channel
New Blood Biomarker Predicts May Predict Preeclampsia and Fetal Growth Restriction
Preeclampsia and fetal growth restriction are major drivers of stillbirth and serious maternal morbidity, yet clinicians still lack reliable early predictors to guide targeted surveillance.... Read more
Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction
Takotsubo syndrome, often called broken-heart syndrome, mimics myocardial infarction and can be difficult to triage in emergency settings. It accounts for about 2% of suspected heart attacks and up to... Read moreMolecular Diagnostics
view channel
Automated System Streamlines DNA Recovery for MRD-Sensitive Testing
Molecular laboratories are under pressure to detect extremely low levels of residual disease, yet pre-analytical recovery of cell-free and genomic DNA from large-volume blood and plasma remains a persistent... Read more
New Liquid Biopsy Platform Uses Red Blood Cells to Detect Hidden Cancer Signals
Plasma-based liquid biopsy can miss clinically actionable tumor signals, particularly in early-stage disease and low-shedding tumors, limiting its utility for routine monitoring. Clinical laboratories... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read moreMicrobiology
view channel
Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read morePathology
view channel
Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
Peripheral blood mononuclear cells (PBMCs) are widely used to monitor infection, autoimmunity, cancer, and treatment response, yet most assays depend on fluorescent labels that can perturb cells and provide... Read more
AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
Immune checkpoint therapies benefit only a subset of patients, while standard biomarkers often struggle to predict who will respond. Spatially resolved tumor profiling can provide deeper biological context,... Read moreTechnology
view channel
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read more
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read moreIndustry
view channel
New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
Rapid and accurate classification of central nervous system tumors remains a challenge, particularly in children where histology alone can misclassify aggressiveness and drive overtreatment.... Read more







